SAKK 17/18 (ORIGIN) MPM & NSCLC >1st Line Gemci & Atezo Ph II

NCT04480372 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

68

Enrollment

OTHER

Sponsor class

Conditions

Malignant Pleural Mesothelioma
Non-small Cell Lung Cancer

Interventions

DRUG: Gemcitabine
DRUG: Atezolizumab

Sponsor

Swiss Cancer Institute